Trial Profile
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 24 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 21 Jun 2013 Primary endpoint 'Proinsulin-level' has been met.
- 21 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.